Hutch News

Hutch News

Stories tagged 'mini transplant'

A boy, his chicken and a bone marrow transplant

An experimental treatment — and an unconventional pet — offered both hope and healing for Andrew Adams’ rare and debilitating genetic disorder

June 23, 2017 | By Rachel Tompa / Fred Hutch News Service

It took a team of clinicians and years to get Andrew Adams to the other side of his life-threatening symptoms. Throughout it all, his beloved pet chicken Frightful kept his spirits up.

View story >

Three's a charm in a triple-drug combination for transplant patients

A drug with a storied past offers a new edge against an old foe

Dec. 4, 2016 | By Sabin Russell / Fred Hutch News Service

Discovered nearly 45 years ago in the volcanic soils of fabled Easter Island in the Pacific, a drug first thought of as an antifungal agent has found a new purpose by boosting the survival of leukemia patients after blood stem cell transplants. In a clinical trial conducted by Fred Hutchinson Cancer Research Center, the addition of a third drug, sirolimus, to a standard two-drug regimen effectively cut in half the incidence of acute graft-vs.-host disease, or GVHD, a common and dangerous complication of these lifesaving procedures.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

June 24, 2016

View story >

From building toys to developing cures

At 80, transplant scientist Dr. Rainer Storb can't stop tinkering with — and solving — medical puzzles

Dec. 21, 2015 | By Susan Keown / Fred Hutch News Service

Dr. Rainer Storb loves seeing and catching up with his former patients - men and women saved by his own research. He's 80 with big research goals still ahead.

View story >

Life with graft-vs.-host disease: When the transplant is just the beginning

How researchers are trying to combat this common, often debilitating side effect of treatment

April 21, 2015 | By Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant recipients, such as Greg Grappone, develop acute graft-vs.-host disease, which crops up within the first few months of treatment, and 40 percent get chronic GVHD, the form that appears more than 100 days post-transplant. As the name implies, the chronic condition can last for years — or a lifetime — and its symptoms range from mildly annoying to disabling to life-threatening.

View story >

Gentler treatment effective for many with graft-vs.-host disease

A new study finds halving standard steroid dose treats most acute GVHD just as well; could limit dangerous side effects

Feb. 19, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant patients develop acute graft-vs.-host disease. Standard treatment for GVHD, the steroid prednisone, carries its own host of side effects. Fred Hutch's Dr. Marco Mielcarek led a new study testing lower doses of prednisone in patients with acute GVHD -- with promising results.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.